Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro
/in Gastric Cancer, International Publications /von 2007-08-23 / Tumour Biol. 2007;28(4):238-46Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects
/in HIV/AIDS, International Publications /von 2007-08-20 / AIDS 2007 Aug;21(13):1683-92Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity
/in Dendritic Cells, Hyperthermia, International Publications, Prostate Cancer /von 2007-08-15 / Cancer Res. 2007 Aug;67(16):7798-806Dendritic cell vaccination
/in Breast Cancer, Colorectal Cancer, Hypernephroma, International Publications, Malignant Melanoma, Prostate Cancer /von 2007-08-01 / Expert Rev Vaccines 2007 Aug;6(4):617-33Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study
/in Hyperthermia, International Publications, Prostate Cancer /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):451-6Benefits of superficial hyperthermia treatment planning: five case studies
/in Breast Cancer, Hyperthermia, International Publications, Malignant Melanoma /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):417-29Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
/in Hyperthermia, International Publications, Malignant Pleural Mesothelioma /von 2007-08-01 / Int J Hyperthermia 2007 Aug;23(5):431-42Immunotherapy with dendritic cells for prostate cancer
/in International Publications, Prostate Cancer /von 2007-08-01 / Int. J. Cancer 2007 Aug;121(3):467-73Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge)
/in International Publications, Prostate Cancer /von 2007-08-01 / Expert Opin Biol Ther 2007 Aug;7(8):1275-80
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution